MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2020 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter ended 30th June, 2020. MARKSANS PHARMA LTD. - 524404 - Shareholding for the Period Ended June 30, 2020
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2020 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company. MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
Trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the insiders of the Company will remain closed with effect from Wednesday, 1st July, 2020 till 48 hours after the declaration of financial results for the quarter ended 30th June, 2020. The date of declaration of financial results will be intimated separately in due course of time. MARKSANS PHARMA LTD. - 524404 - Revised Related Party Transactions Disclosure For The Half Year Ended 31St March, 2020.
With reference to our letter of even date pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith revised disclosure of related party transactions for the half year ended 31st March, 2020. The financial results for the quarter and year ended 31st March, 2020 both standalone and consolidated were published on 2nd June, 2020. MARKSANS PHARMA LTD. - 524404 - Related Party Transactions Disclosure For The Half Year Ended 31St March, 2020.
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosures of related party transactions for the half year ended 31st March, 2020. The financial results for the quarter and year ended 31st March, 2020 both standalone and consolidated were published on 2nd June, 2020.
Slideshow | These 6 BSE stocks doubled investor money in less than 6 months
Marksans Pharma share price surged 102 percent in 2020 so far. However, the period between January 1 to March 23, this stock price was down 37 percent. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investor Meeting MARKSANS PHARMA LTD. - 524404 - Declaration Regarding Non Applicability Of SEBI Circular Dated 26Th November, 2018
Pursuant to SEBI Circular No. SEBI/ HO/DDHS/CIR/P/2018/144 dated November 26, 2018, we would like to inform you that Marksans Pharma Limited does not fall under the category of "Large Corporate" as per the applicability criteria mentioned in the above SEBI Circular with respect to fund raising by issuance of Debt Securities by Large Entities.